KPV vs TB4-Frag (TBF)
A side-by-side research comparison of KPV and TB4-Frag (TBF) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | KPV | TB4-Frag (TBF) |
|---|---|---|
| Full name | Lysine-Proline-Valine Tripeptide | Thymosin Beta-4 Fragment |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Inhibits NF-kB signaling pathway, reduces pro-inflammatory cytokine production (TNF-α, IL-6), and modulates immune cell activation. | Retains the actin-sequestering motif of full TB-4, promoting cell migration, angiogenesis, and reduction of inflammation at injury sites. The shorter sequence may offer improved bioavailability and targeted tissue penetration. |
| Molecular weight | 342.43 Da | ~1,200-1,800 Da (fragment) |
| Half-life | ~2-3 hours | ~2-4 hours |
| Bioavailability | ~60-70% oral; higher subcutaneous | High subcutaneous absorption |
| Typical dose | 200-500 mcg per dose | 200-750 mcg per dose |
| Frequency | 1-2x daily | Daily or every other day |
| Route | Oral, topical, or subcutaneous | Subcutaneous injection |
KPV reported benefits
- Potent anti-inflammatory
- Gut inflammation reduction
- Skin condition improvement
- Immune modulation
TB4-Frag (TBF) reported benefits
- Wound and tissue healing
- Reduced inflammation
- Potential improved tissue penetration vs full TB-4
- Support for tendon and muscle repair
- Angiogenesis promotion
Related comparisons
Research and educational reference only. Not medical advice.